162 related articles for article (PubMed ID: 28130691)
1. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
Cowles E; Marsden G; Cole A; Devlin N
Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
[TBL] [Abstract][Full Text] [Related]
2. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
3. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
4. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
5. An assessment of the impact of the NHS Health Technology Assessment Programme.
Hanney S; Buxton M; Green C; Coulson D; Raftery J
Health Technol Assess; 2007 Dec; 11(53):iii-iv, ix-xi, 1-180. PubMed ID: 18031652
[TBL] [Abstract][Full Text] [Related]
6. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
Davies E; Littlejohns P
J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
[TBL] [Abstract][Full Text] [Related]
7. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
Buxton M
Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
[TBL] [Abstract][Full Text] [Related]
8. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
10. Evidence informed decision making: the use of "colloquial evidence" at nice.
Sharma T; Choudhury M; Kaur B; Naidoo B; Garner S; Littlejohns P; Staniszewska S
Int J Technol Assess Health Care; 2015 Jan; 31(3):138-46. PubMed ID: 25991028
[TBL] [Abstract][Full Text] [Related]
11. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
12. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
13. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
[TBL] [Abstract][Full Text] [Related]
14. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
15. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Towse A; Pritchard C
Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
[TBL] [Abstract][Full Text] [Related]
16. Use of Expert Judgement Across NICE Guidance-Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation.
Peel A; Jenks M; Choudhury M; Lovett R; Rejon-Parrilla JC; Sims A; Craig J
Appl Health Econ Health Policy; 2018 Dec; 16(6):819-836. PubMed ID: 30073485
[TBL] [Abstract][Full Text] [Related]
17. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
18. Evidence-informed evidence-making.
Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
[TBL] [Abstract][Full Text] [Related]
19. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
20. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]